Breakthrough in Digital Therapy for Schizophrenia: CT-155 Shows Promising Results
Ingelheim, Friday, 8 August 2025.
Boehringer Ingelheim and Click Therapeutics report success with CT-155 digital therapy, effectively reducing negative schizophrenia symptoms, marking a significant advancement in mental health treatment.
The CONVOKE Study: A Landmark in Schizophrenia Treatment
The latest results from the CONVOKE study, a Phase III clinical trial, reveal a pivotal advancement in the treatment of schizophrenia. Conducted by Boehringer Ingelheim and Click Therapeutics, the study evaluated the effectiveness of CT-155, an investigational prescription digital therapeutic (PDT), as an adjunct to standard antipsychotic therapies. The CONVOKE study was designed as a rigorous, 16-week, randomized, double-blind, and controlled trial aimed at assessing the therapeutic potential of CT-155 in mitigating negative symptoms such as lack of motivation and pleasure, commonly experienced by individuals with schizophrenia [1][2].
Impact on Schizophrenia Management
Approximately 2.8 million adults in the United States are affected by schizophrenia, with about 60% experiencing negative symptoms, which significantly impair daily functioning and quality of life [1][2]. The successful outcome of the CONVOKE study, which CT-155 reportedly met its primary endpoint, marks the first Phase III evidence for a digital therapeutic in treating a core element of schizophrenia. This finding underscores the potential of CT-155 to transform existing treatment paradigms and provide a non-invasive, easily accessible therapeutic option for managing negative symptoms [1][3].
The Role of Digital Therapeutics
Digital therapeutics such as CT-155 signify a shift towards integrating technology and healthcare to create patient-centric treatments. Unlike traditional medications, digital therapeutics provide interventions through platforms like smartphones, allowing continuous monitoring and engagement. CT-155 leverages advanced software to deliver behavioral therapy tailored to the individual’s needs, enhancing treatment adherence and effectiveness [1]. This innovative approach not only highlights the intersection of neuroscience and digital technology but also reinforces Click Therapeutics’ commitment to redefine modern medicine by providing scalable therapeutic solutions [1][2].
Future Perspectives and Regulatory Recognition
Further comprehensive data and findings from the CONVOKE study are to be presented at the 38th Annual European College of Neuropsychopharmacology Congress in Amsterdam on October 13, 2025. Meanwhile, CT-155 has received the Breakthrough Device designation by the U.S. Food and Drug Administration, pointing towards accelerated development and review processes [1][2]. This regulatory milestone reflects both the innovation and the promising clinical relevance of CT-155, potentially streamlining the integration of digital therapeutics into mainstream schizophrenia treatment protocols [2][3].